Creative Medical Technology issues mid-year pipeline update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Creative Medical Technology Holdings Issues Mid-Year Update
July 1, 2026 9:00 AM EDTPHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (Creative Medical or the Company), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.
Dear Fellow Shareholder:
Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (OA), immunotherapy, and biodefense.
This progress, combined with disciplined capital allocation and expanding non-dilutive opportunities, positions the Company for durable value creation... More



